
Mankind Pharma Ltd. share price
NSE: MANKIND · Healthcare
₹2,626.60 -0.51%
Closing price data, updated 17 Nov 2026. 52-week range: -2.9% from high, +37.5% above low.
Price₹2,626.60
Market cap₹1,08,490 Cr
P/E48.4
P/B6.17
ROE12.5%
ROCE13.8%
Debt / equity0.39
Dividend yield0.00%
EPS₹54.30
Book value₹425.67
Operating margin19.9%
Dipscan score48 / 100
Share: WhatsAppX / TwitterTelegram
Mankind Pharma Ltd. shareholding pattern
As of Sep 2026: Promoters 72.62%, FIIs 9.37%, DIIs 15.56%, Government 0.00%, Public 1.26%, Others 1.19%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 72.62% | 72.63% | 72.66% | 72.66% | 72.67% | 72.68% |
| FIIs | 9.37% | 9.45% | 10.24% | 11.34% | 12.84% | 13.07% |
| DIIs | 15.56% | 15.39% | 14.46% | 13.25% | 11.92% | 11.50% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 1.26% | 1.29% | 1.39% | 1.52% | 1.36% | 1.52% |
| Others | 1.19% | 1.24% | 1.25% | 1.23% | 1.21% | 1.23% |
| No. of Shareholders | 163,770 | 166,715 | 177,606 | 177,539 | 170,347 | 179,549 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.51% | +3.41% | +12.49% | +9.24% | +6.68% | +18.29% |
Growth
| Sales growth, 3 years | +17.7% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +14.3% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company has reduced debt.
Weaknesses
- Promoter holding has decreased over last 3 years: -3.88%
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Mankind Pharma Ltd.?
Mankind Pharma Ltd. (MANKIND) last closed at ₹2,626.60 (-0.51% on the day).
What is the market cap of Mankind Pharma Ltd.?
About ₹1,08,490 Cr.
What is the P/E ratio of Mankind Pharma Ltd.?
The price-to-earnings ratio is 48.4, and return on equity is 12.5%.
Figures are calculated from company results and exchange prices and are for information only.